interaction,anti-inflammatory

Resatorvid (TAK-242), a selective Toll-like receptor 4 (TLR4) inhibitor, binds directly to Cys747 to prevent TLR4-TIRAP interaction, thereby blocking downstream signaling. Resatorvid exhibits antitumor, anti-inflammatory, and neuroprotective activities.

Anti-inflammatory agent 49 is a potent inhibitor of Drp1-Fis1 interaction, inhibits GTPase, and can be used in the study of diseases caused by mitochondrial dysfunction.

Trypsin is a serine protease that can be isolated from fish to hydrolyze lysine or arginine carboxy-side proteins. With the anti-inflammatory activity, Trypsin could induce the cell membrane fusion of PDCoV-infected cells through the interaction between the S glycoprotein of PDCoV and pAPN, activate PAR2 and PAR4, and promote cell proliferation and differentiation. Trypsin can be used to promote wound healing and study neurogenic inflammation.

BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity.

Natalizumab is a recombinant humanized monoclonal antibody and a humanized monoclonal antibody inhibitor that selectively targets α4 integrin (CD49d). Natalizumab binds to the α4β1 heterodimer and blocks its interaction with vascular cell adhesion molecule 1. Natalizumab also prevents lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses, and is used in the study of relapsing-remitting multiple sclerosis and Crohn’s disease. Natalizumab possesses anti-inflammatory and immunomodulatory activity, inhibiting the adhesion, retention, and transendothelial migration of immune cells, and reducing the infiltration of inflammatory cells into the central nervous system or affected sites. Natalizumab is also being studied for autoimmune or inflammation-related diseases such as B-cell lymphoma and non-infectious uveitis.

Carotegrast is a selective α4 integrin antagonist that inhibits the migration of inflammatory cells to the intestinal mucosa by blocking the interaction between α4β1/α4β7 integrins and their ligands. Carotegrast is used in research and clinical practice for the treatment of inflammatory bowel diseases such as ulcerative colitis; it exerts local anti-inflammatory effects and results in low systemic exposure.

CD-10 is an orally active inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI) that can penetrate the blood-brain barrier. It binds to Keap1 with a KD value of 193 nM. CD-10 exerts significant antioxidant and anti-inflammatory effects by activating the Keap1-Nrf2 pathway, demonstrated by reduced levels of MDA, IL-4, and IL-10, and increased expression of HO-1 protein. In a chronic unpredictable mild stress (CUMS) mouse model, CD-10 effectively alleviates anxiety and depressive behaviors and restores serum neurotransmitter levels by promoting Nrf2 nuclear translocation. CD-10 is applicable for research in depression.

Nrf2 activator-20 is a potent Nrf2 activator with anti-inflammatory and antioxidant properties. It activates anti-inflammatory pathways by disrupting the interaction between Keap1 and Nrf2, demonstrating beneficial effects in vivo. Nrf2 activator-20 is applicable for studies on acute respiratory distress syndrome (ARDS) and ischemia-reperfusion injury.

MyD88-IN-3 is an orally active, selective MyD88 inhibitor that specifically targets the TIR domain of MyD88 (KD= 28.5 μM). It prevents MyD88 self-aggregation and its interaction with TLRs, thereby suppressing the activation of the MAPK and NF-κB pathways. MyD88-IN-3 exhibits significant anti-inflammatory effects and effectively alleviates symptoms of acute lung injury in CLP (cecal ligation and puncture) and LPS (lipopolysaccharide)-induced ALI models. This compound is valuable for ALI research.

MyD88-IN-4 is a MyD88 inhibitor. It exerts antiviral effects by upregulating IFN-β and demonstrates anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines. MyD88-IN-4 prevents the formation of MyD88 homodimers and interferes with its interaction with IRF3/IRF7. In a mouse model infected with VEEV TC-83, MyD88-IN-4 shows efficacy against encephalitic alphavirus infections by reducing viral replication and increasing survival rates. This compound is applicable for research on alphavirus infections, bacterial toxin-related diseases, and sepsis.

Jamaicin (AnCoA4) is a natural product, a STIM1-Orai1 channel inhibitor that blocks calcium influx and suppresses T cell activation. This compound possesses cellular permeability and is used for research related to immunomodulation, demonstrating potential anti-inflammatory activity.

Naringenin chalcone (Isosalipurpol) has antiallergic activity Naringenin chalcone suppresses asthmatic symptoms by inhibiting Th2 cytokine production from CD4 T cells. Naringenin chalcone is a potent tomato flavonoid that improves adipocyte metabolic functions and exerts insulin-sensitizing effects by activating an adiponectin-related pathway. Naringenin chalcone exhibits anti-inflammatory properties by inhibiting the production of proinflammatory cytokines in the interaction between adipocytes and macrophages, may be useful for ameliorating the inflammatory changes in obese adipose tissue.

Benpyrine is a highly specific and orally active TNF-α inhibitor with a KD value of 82.1 μM and an IC50 value of 0.109 μM. It tightly binds to TNF-α, blocking its interaction with TNFR1, and has potential for TNF-α mediated inflammatory and autoimmune disease research [1].

Nexinhib20 is an inhibitor of exosome synthesis and transport with anti-inflammatory activity, inhibits RAB27A and neutral sphingomyelinase 2 (nSMase2) nsMase2, inhibits IL-8-induced β(2) integrin-dependent adhesion of human neutrophils in the subfluidic phase, and inhibits neutrophil adhesion and β(2) integrin activation through antagonism of the rac-1-guanosine 5'-triphosphate interaction. beta(2) integrin activation.

Maraviroc (UK-427857, Selzentry) belongs to small molecule drugs and is a C-C chemokine receptor 5 antagonist with oral activity and selectivity. This compound is used for the treatment of HIV-1 infection and has also shown anti-inflammatory, neuroprotective, and potential antitumor synergistic effects in research.

α-Amylase-IN-3 is a multi-target inhibitor of α-amylase (IC50=18.04 μM) and cholinesterases (AChE/BChE). It exhibits antioxidant activity for diabetes and neurodegeneration research.

Keap1-Nrf2-IN-14 is a KEAP1-NRF2 inhibitor that effectively disrupts the KEAP1-NRF2 interaction (IC50: 75 nM) with a Kd=24 nM for KEAP1. Keap1-Nrf2-IN-14 induces the expression of NRF2 target genes and is able to enhance downstream antioxidant and anti-inflammatory effects. -Nrf2-IN-14 can be used to study oxidative stress-related inflammation.

Antimicrobial Agent-5 is a potent antimicrobial agent that exhibits exceptional cell selectivity against both Gram-negative and Gram-positive bacteria. It inhibits the interaction between LPS (lipopolysaccharide) and the CD14/TLR4 (Toll-like receptor 4) receptor, demonstrating anti-inflammatory activity in combating LPS-induced inflammation.

Bufrolin, an analog of Cromoglycate (histamine release inhibitor) and a potent agonist of GPR35, enhances the interaction between β-arrestin-2 and both human GPR35a and rat GPR35. It stabilizes mast cells, exhibiting antiallergic properties, and inhibits anti-inflammatory responses triggered by internalization peptides. Furthermore, Bufrolin is researched for its anti-inflammatory properties in pharmaceutic applications associated with internalization peptides [1] [2] [3].

Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 receptor interaction and subsequent downstream signaling and can be used to study atopic dermatitis (AD).

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF). Otilimab has anti-inflammatory activity, regulates the biological function of GM-CSF by blocking the interaction between GM-CSF and its cell surface receptors, and can be used in studies to treat severe COVID-19 pneumonia.

Ontamalimab is a highly specialized fully human monoclonal antibody target mucosal addressin cell adhesion molecule-1 (MAdCAM-1), inhibition of lymphocyte homing to the gastrointestinal mucosa by disrupting the interaction between MAdCAM-1 and the α 4 β 7 integrin across various inflammatory models.

Aletekitug is a humanized antibody that targets IL-18. Alekitug binds to free IL-18, thereby blocking its interaction with the IL-18 receptor α/β heterodimer and preventing receptor activation. This inhibits the release of pro-inflammatory cytokines, reduces the infiltration of immune cells at sites of inflammation, and exerts an anti-inflammatory effect. Alekitug can be used in research on inflammatory conditions such as inflammatory bowel disease.